A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
← catalyst calendarNCT07192614 · readout in 953 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
52estimated
Sites
26
Countries
Belgium, Canada, China +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-30 | actual | When the study began enrolling |
| Primary completion | 2029-03-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-03-29 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Prostate Cancer
Intervention
- Drug: AZD6621
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events (AE), adverse events of special interest (AESI), and serious adverse events (SAE)
measured From time of Informed Consent to 90 days post last dose of study intervention (up to 3 years)
Number of participants with dose-limiting toxicity (DLT), as defined in the protocol (Part A only)
measured From first study dose to 21 to 28 days post first dose
Preliminary anti-tumour activity of AZD6621 (PSA Response Rate) (Part B only)
measured Up to 3 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed